Can Irisin be a New Agent Responsible for the Development of Heart Attack and Cardiac Cachexia?
Main Article Content
Downloads
Article Details
Copyright (c) 2016 Suna Aydin.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Evans WJ, Morley JE, Argile's J, Bales C, Baracos V, et al. (2008) Cachexia: a new definition. Clin Nutr 27: 793–799 .
Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, et al. (2013) Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine 43: 626-634 .
Pittman JG, Cohen P (1964) The Pathogenesis of Cardiac Cachexia. N Engl J Med 271: 453-460 .
Cohen S, Nathan JA, Goldberg AL (2015) Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 14: 58-74 .
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, et al. (2012) A PGC1-?-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 11: 463-468 .
Aydin S (2014) Three new players in energy regulation: preptin, adropin and irisin. Peptides 56: 94-110 .
Depre C, Vanoverschelde JL, Taegtmeyer H (1999) Glucose for the heart. Circulation 99: 578-588.
Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, et al. (2016) The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation 133: 698-705 .
Ingwall JS, Weiss RG (2004) Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 95: 135-145 .
Page E, McCallister LP (1973) Quantitative electron microscopic description of heart muscle cells. Application to normal, hypertrophied and thyroxin-stimulated hearts. Am J Cardiol 31: 172-181 .